NEWSROOM Press Releases

    254 Results

    Biodesix Announces Third Quarter 2023 Results and Highlights

    Biodesix Inc. announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.

    Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

    Discover key insights from Biodesix at CHEST 2023 on Nodify Lung® tests, impacting pulmonary nodule management and reducing invasive procedures.

    Biodesix to Participate in Two Upcoming Investor Conferences in September

    Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.

    Biodesix to Participate in Two Upcoming Investor Conferences in November

    Biodesix announced Scott Hutton, CEO, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference

    Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

    Biodesix announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.

    Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

    Biodesix announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7.

    Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

    Biodesix reveals key NSCLC proteomic test data at IASLC 2023, highlighting VeriStrat's predictive power and the Risk of Recurrence test's precision

    Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

    Biodesix reveals ORACLE study results: Nodify XL2 test effectively identifies benign lung nodules, leading to a 51% increase in lung cancer diagnosis rates and fewer invasive procedures.

    Biodesix Announces Second Quarter 2023 Results and Highlights

    Biodesix Q2 2023: Core Lung Diagnostic revenue at $11.4M (up 58% YoY), 73% profit margin. 2023 guidance: $52-55M. $27.5M private shares sold.

    Biodesix Participates in Canaccord Genuity Annual Growth Conference

    Biodesix CEO to present at Canaccord Genuity's 43rd Annual Growth Conference on Aug 9, 2023. Discover data-driven lung disease solutions at Biodesix.com.

    1 2 3 4 5 6 7 8 9